Aduro Biotech, Inc. (NASDAQ:ADRO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On March 1, 2017, Aduro Biotech, Inc. (Aduro) announced certain
financial results for its fourth quarter and year ended December
31, 2016. A copy of Aduros press release, titled Aduro Biotech
Announces Fourth Quarter and Full Year 2016 Financial Results, is
furnished to Item 2.02 as Exhibit 99.1 hereto.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
Exhibit |
Description |
|
99.1 |
Press Release, dated March 1, 2017, titled Aduro Biotech |
The information in this report, including the exhibit hereto,
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibit shall not be incorporated
by reference into any filing with the U.S. Securities and
Exchange Commission made by Aduro Biotech, Inc., whether made
before or after the date hereof, regardless of any general
incorporation language in such filing.
About Aduro Biotech, Inc. (NASDAQ:ADRO)
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development. Aduro Biotech, Inc. (NASDAQ:ADRO) Recent Trading Information
Aduro Biotech, Inc. (NASDAQ:ADRO) closed its last trading session 00.00 at 11.25 with 242,410 shares trading hands.
